(Q43868280)

27 November 2017

title

The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease (English)

1 reference

27 November 2017

J P Larsen

1

1 reference

27 November 2017

J Worm-Petersen

2

1 reference

27 November 2017

A Sidén

3

1 reference

27 November 2017

A Gordin

4

1 reference

27 November 2017

K Reinikainen

5

1 reference

27 November 2017

M Leinonen

6

1 reference

27 November 2017

NOMESAFE Study Group

7

1 reference

27 November 2017

language of work or name

1 reference

1 March 2003

1 reference

European Journal of Neurology

27 November 2017

published in

1 reference

27 November 2017

volume

10

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

137-146

1 reference

Parkinsonism: onset, progression, and mortality

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00559.X

General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00559.X

Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00559.X

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00559.X

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2003.00559.X

10.1046/J.1468-1331.2003.00559.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference